CN113198003A - 一种用于皮肤损伤后预防萎缩性疤痕外用液及其制备方法 - Google Patents
一种用于皮肤损伤后预防萎缩性疤痕外用液及其制备方法 Download PDFInfo
- Publication number
- CN113198003A CN113198003A CN202110689426.2A CN202110689426A CN113198003A CN 113198003 A CN113198003 A CN 113198003A CN 202110689426 A CN202110689426 A CN 202110689426A CN 113198003 A CN113198003 A CN 113198003A
- Authority
- CN
- China
- Prior art keywords
- growth factor
- external liquid
- skin injury
- parts
- atrophic scars
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 68
- 231100000241 scar Toxicity 0.000 title claims abstract description 54
- 208000032544 Cicatrix Diseases 0.000 title claims abstract description 51
- 230000037387 scars Effects 0.000 title claims abstract description 51
- 208000028990 Skin injury Diseases 0.000 title claims abstract description 40
- 238000002360 preparation method Methods 0.000 title abstract description 17
- 239000002994 raw material Substances 0.000 claims abstract description 32
- 239000004863 Frankincense Substances 0.000 claims abstract description 30
- 235000008434 ginseng Nutrition 0.000 claims abstract description 27
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims abstract description 26
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims abstract description 26
- 229940126864 fibroblast growth factor Drugs 0.000 claims abstract description 26
- 239000012530 fluid Substances 0.000 claims abstract description 26
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims abstract description 26
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 25
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 25
- 210000005059 placental tissue Anatomy 0.000 claims abstract description 25
- 101800003838 Epidermal growth factor Proteins 0.000 claims abstract description 24
- 229940116977 epidermal growth factor Drugs 0.000 claims abstract description 24
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 claims abstract description 23
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 claims abstract description 23
- 229950006790 adenosine phosphate Drugs 0.000 claims abstract description 23
- 240000007551 Boswellia serrata Species 0.000 claims abstract description 22
- 235000012035 Boswellia serrata Nutrition 0.000 claims abstract description 22
- 238000000034 method Methods 0.000 claims abstract description 22
- 235000003717 Boswellia sacra Nutrition 0.000 claims abstract description 21
- 238000002156 mixing Methods 0.000 claims abstract description 21
- 240000007311 Commiphora myrrha Species 0.000 claims abstract description 19
- 235000006965 Commiphora myrrha Nutrition 0.000 claims abstract description 19
- 235000007265 Myrrhis odorata Nutrition 0.000 claims abstract description 19
- 235000006533 astragalus Nutrition 0.000 claims abstract description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
- 241001674044 Blattodea Species 0.000 claims abstract description 16
- 241000147041 Guaiacum officinale Species 0.000 claims abstract description 14
- 229940091561 guaiac Drugs 0.000 claims abstract description 14
- 241001061264 Astragalus Species 0.000 claims abstract description 12
- 210000004233 talus Anatomy 0.000 claims abstract description 12
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 11
- 239000000706 filtrate Substances 0.000 claims abstract description 10
- 239000000203 mixture Substances 0.000 claims abstract description 10
- 206010052428 Wound Diseases 0.000 claims abstract description 9
- 238000001914 filtration Methods 0.000 claims abstract description 9
- 238000002791 soaking Methods 0.000 claims abstract description 8
- 238000005303 weighing Methods 0.000 claims abstract description 7
- 239000002023 wood Substances 0.000 claims abstract description 6
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims abstract 4
- 241000238659 Blatta Species 0.000 claims description 16
- 235000004440 Guaiacum sanctum Nutrition 0.000 claims description 14
- 241000238661 Periplaneta Species 0.000 claims description 13
- 241000717739 Boswellia sacra Species 0.000 claims description 9
- 241001057584 Myrrha Species 0.000 claims description 9
- 241000045403 Astragalus propinquus Species 0.000 claims description 6
- 238000001804 debridement Methods 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 6
- 238000007789 sealing Methods 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 3
- 240000004371 Panax ginseng Species 0.000 claims 5
- 240000006982 Guaiacum sanctum Species 0.000 claims 2
- 235000002789 Panax ginseng Nutrition 0.000 claims 2
- 239000011259 mixed solution Substances 0.000 claims 2
- 229940107666 astragalus root Drugs 0.000 claims 1
- 230000000717 retained effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 17
- 230000001737 promoting effect Effects 0.000 abstract description 10
- 230000008439 repair process Effects 0.000 abstract description 7
- 210000002950 fibroblast Anatomy 0.000 abstract description 4
- 102000008186 Collagen Human genes 0.000 abstract description 3
- 108010035532 Collagen Proteins 0.000 abstract description 3
- 229920001436 collagen Polymers 0.000 abstract description 3
- 230000008929 regeneration Effects 0.000 abstract description 3
- 238000011069 regeneration method Methods 0.000 abstract description 3
- 230000036560 skin regeneration Effects 0.000 abstract description 3
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 241000208340 Araliaceae Species 0.000 description 21
- 102400001368 Epidermal growth factor Human genes 0.000 description 20
- 241000190019 Guaiacum Species 0.000 description 12
- 239000003814 drug Substances 0.000 description 11
- 239000009636 Huang Qi Substances 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 230000007812 deficiency Effects 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 239000000047 product Substances 0.000 description 6
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 206010003549 asthenia Diseases 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 206010007247 Carbuncle Diseases 0.000 description 3
- 208000017667 Chronic Disease Diseases 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 3
- 230000007797 corrosion Effects 0.000 description 3
- 238000005260 corrosion Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 2
- 208000031091 Amnestic disease Diseases 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 241000208229 Burseraceae Species 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010061876 Obstruction Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 230000006986 amnesia Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000011278 mitosis Effects 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000000552 rheumatic effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 206010044008 tonsillitis Diseases 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 241000238662 Blatta orientalis Species 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000218176 Corydalis Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 241000845082 Panama Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 241000238675 Periplaneta americana Species 0.000 description 1
- 206010060932 Postoperative adhesion Diseases 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000003734 Supraventricular Tachycardia Diseases 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 241000159213 Zygophyllaceae Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 210000001992 atrioventricular node Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 206010007625 cardiogenic shock Diseases 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 210000001711 oxyntic cell Anatomy 0.000 description 1
- 230000007119 pathological manifestation Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000019643 salty taste Nutrition 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- -1 stomach invigorating Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Insects & Arthropods (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Animal Husbandry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了一种用于皮肤损伤后预防萎缩性疤痕外用液及其制备方法,该方法包含:步骤1、按比例称取各原料;步骤2、将大蜚蠊用白酒浸泡,然后进行萃取;步骤3、将黄芪、人参、没药、乳香、愈创木,加水煎煮,浓缩,过滤保留滤液;步骤4、将成纤维细胞生长因子、表皮生长因子、磷酸腺苷、胎盘组织液混合均匀;步骤5、将步骤2和步骤3所得的液体混合,再加入步骤4所得的混合物,混合均匀。本发明还提供了该方法制备的用于皮肤损伤后预防萎缩性疤痕外用液。本发明提供的外用液,具有促进创面再生的功效,能够使成纤维细胞生长增殖产生较多胶原,从而达到预防萎缩性疤痕的形成,针对性解决具有发生萎缩的疤痕的皮肤再生修复能力弱的问题。
Description
技术领域
本发明涉及一种医疗美容药物领域中用于皮肤损伤后预防疤痕的药液及其制备方法,具体地,涉及一种用于皮肤损伤后预防萎缩性疤痕外用液及其制备方法。
背景技术
在皮肤受到物理性损伤后,皮肤愈合过程中会形成疤痕,在病理表现上常见的是增生性和萎缩性,也就是凸出凹陷。而目前市场上包括医院药店,多见硅酮、甘油、硬脂酸、凡士林等成份组成的防疤痕产品,这些成份的作用原理主要是保湿作用,通过保持表皮层的水份,也就是水化作用来间接达到预防疤痕和软化疤痕,所以这种产品的作用相对较弱,临床使用时间长,效果慢,病人花费高。
另外,疤痕的形成是一个动态的综合的多种因素的过程结果,它不只是与水分丢失有关,还与炎性期的时间长短、表皮生长周期的延长、成纤维细胞的分裂增殖、合成胶原纤维的能力、胶原酶的活性等,都有密切关系。特别是疤痕疙瘩于毛细血管内皮细胞润性生长为主要原因之一。
发明内容
本发明的目的是提供一种用于皮肤损伤后预防疤痕的药液及其制备方法,能够达到修复表皮组织、防腐生肌、愈后不留疤痕特别是萎缩性疤痕等效果,外用没有副作用,而且药物配方简单,经济实惠。
为了达到上述目的,本发明提供了一种用于皮肤损伤后预防萎缩性疤痕外用液的制备方法,其中,所述的方法包含:步骤1、按比例称取各原料;所述的原料包含大蜚蠊、黄芪、人参、没药、乳香、愈创木、白酒、水,以及成纤维细胞生长因子、表皮生长因子、磷酸腺苷、胎盘组织液;步骤2、将大蜚蠊用白酒浸泡,然后进行萃取;步骤3、将黄芪、人参、没药、乳香、愈创木,加水煎煮,再继续加热浓缩,然后过滤,保留滤液;步骤4、将成纤维细胞生长因子、表皮生长因子、磷酸腺苷、胎盘组织液混合均匀;步骤5、将步骤2和步骤3所得的液体混合,再加入步骤4所得的混合物,混合均匀后装瓶密封备用。
上述的用于皮肤损伤后预防萎缩性疤痕外用液的制备方法,其中,所述的原料中包含大蜚蠊80~120份,黄芪25~35份,人参5~15份,没药1~5份,乳香1~5份,愈创木5~15份。
上述的用于皮肤损伤后预防萎缩性疤痕外用液的制备方法,其中,所述的原料中包含大蜚蠊100g,黄芪30g,人参10g,没药3g,乳香3g,愈创木10g。
上述的用于皮肤损伤后预防萎缩性疤痕外用液的制备方法,其中,所述的原料中还包含成纤维细胞生长因子8~12份,表皮生长因子4~6份,磷酸腺苷1~3份,胎盘组织液1~3份。
上述的用于皮肤损伤后预防萎缩性疤痕外用液的制备方法,其中,所述的原料中还包含成纤维细胞生长因子10g,表皮生长因子5g,磷酸腺苷2ml,胎盘组织液2ml。
上述的用于皮肤损伤后预防萎缩性疤痕外用液的制备方法,其中,所述的步骤2中,将大蜚蠊用56°白酒浸泡五天,然后进行萃取,得到萃取液100ml。
上述的用于皮肤损伤后预防萎缩性疤痕外用液的制备方法,其中,所述的步骤3中,将黄芪、人参、没药、乳香、愈创木,加水500ml煎煮,再加热浓缩为100ml,然后过滤,保留滤液。
上述的用于皮肤损伤后预防萎缩性疤痕外用液的制备方法,其中,所述的步骤5中,将步骤2和步骤3所得的液体按体积比1:1混合,得到200ml混合液,再加入步骤4所得的混合物,混合均匀。
本发明还提供了上述的方法制备的用于皮肤损伤后预防萎缩性疤痕外用液。
上述的用于皮肤损伤后预防萎缩性疤痕外用液,其中,所述的外用液在皮肤损伤清创缝合使伤口基本愈合后,从第8天开始涂抹,一天涂抹3回,每回在第一次涂抹药液吸收后,再连续重复涂抹2次。
本发明提供的用于皮肤损伤后预防萎缩性疤痕外用液及其制备方法的具有以下优点:
本发明提供的用于皮肤损伤后预防萎缩性疤痕外用液,能够修复表皮组织、防腐生肌,伤口愈合后不留疤痕。该药液配方简单,经济实惠,配制过程容易,设备和原材料等来源广泛,成本低廉,使用方便。
本发明配方具有促进创面再生的功效,能够使成纤维细胞生长增殖产生较多胶原,从而达到预防萎缩性疤痕的形成,针对性解决具有发生萎缩的疤痕的皮肤再生修复能力弱的问题。可以主要用于皮肤的物理性损伤在医疗处理后的疤痕特别是萎缩性疤痕的预防。
具体实施方式
以下对本发明的具体实施方式作进一步地说明。
本发明提供的用于皮肤损伤后预防萎缩性疤痕外用液的制备方法,其包含:步骤1、按比例称取各原料;该原料包含大蜚蠊、黄芪、人参、没药、乳香、愈创木、白酒、水,以及成纤维细胞生长因子、表皮生长因子、磷酸腺苷、胎盘组织液;步骤2、将大蜚蠊用白酒浸泡,然后进行萃取;步骤3、将黄芪、人参、没药、乳香、愈创木,加水煎煮,再继续加热浓缩,然后过滤,保留滤液;步骤4、将成纤维细胞生长因子、表皮生长因子、磷酸腺苷、胎盘组织液混合均匀;步骤5、将步骤2和步骤3所得的液体混合,再加入步骤4所得的混合物,混合均匀后装瓶密封备用。
其中,大蜚蠊即大蟑螂。蟑螂泛指属于蜚蠊目的昆虫,药用时采取蜚蠊科大蠊属动物美洲大蠊、澳洲蜚蠊、蜚蠊属动物东方蜚蠊的全体。味咸,性寒。入肝、脾、肾经。具有散瘀,化积,解毒之功效。主治症瘕积聚,小儿疳积,喉痹,乳蛾,痈疮肿毒,虫蛇咬伤。
黄芪为豆科植物蒙古黄芪的根。春、秋季采挖,除去泥土、须根及根头,晒至六七成干,理直扎捆后晒干。性味甘、微温,归肺、脾、肝、肾经,具有增强机体免疫功能、保肝、利尿、抗衰老、抗应激、降压和较广泛的抗菌作用,可用于增加免疫力。
人参为多年生草本植物,自古誉为“百草之王”,“滋阴补生,扶正固本”之极品,含多种皂甙和多糖类成分。人参的肉质根为著名强壮滋补药,适用于调整血压、恢复心脏功能、神经衰弱及身体虚弱等症,也有祛痰、健胃、利尿、兴奋等功效。味甘、微苦,性温、平。归脾、肺经、心经。具有大补元气,复脉固脱,补脾益肺,生津,安神,益智的功效。主治体虚欲脱,肢冷脉微,脾虚食少,肺虚喘咳,津伤口渴,内热消渴,久病虚羸,惊悸失眠,阳痿宫冷;心力衰竭,心原性休克。用于气短喘促,心悸健忘,口渴多汗,食少无力,一切急慢性疾病及失血后引起的休克、虚脱。大补元气,固脱生津,安神。治劳伤虚损,食少,倦怠,反胃吐食,大便滑泄,虚咳喘促,自汗暴脱,惊悸,健忘,眩晕头痛,阳痿,尿频,消渴,妇女崩漏,小儿慢惊,及久虚不复,一切气血津液不足之证。
没药为橄榄科植物地丁树或哈地丁树的干燥树脂。分为天然没药和胶质没药。分布于索马里、埃塞俄比亚及阿拉伯半岛南部等地。味辛、苦,性平。归心、肝、脾经。具有散瘀定痛,消肿生肌的功效。用于胸痹心痛,胃脘疼痛,痛经经闭,产后瘀阻,癥瘕腹痛,风湿痹痛,跌打损伤,痈肿疮疡等病症的治疗。
乳香为橄榄科植物乳香树及同属植物树皮渗出的树脂。分为索马里乳香和埃塞俄比亚乳香,每种乳香又弁为乳香珠和原乳香。性味辛、苦,温。归心、肝、脾经。具有活血行气止痛,消肿生肌的功效。用于胸痹心痛,胃脘疼痛,痛经经闭,产后瘀阻,症瘕腹痛,风湿痹痛,筋脉拘挛,跌打损伤,痈肿疮疡。
愈创木属蒺藜科,是一种常青树木,原产于从巴拿马到西印度群岛的美洲热带地区。愈创木上会产生一种具有药用性能的硬树脂,称愈创木脂。此树脂曾被当作药物用于风湿病和扁桃腺炎的治疗而使愈创木冠有“生命之树”的美誉。有时,愈创木脂也被用于制做止咳糖来缓解咽喉疼痛。
成纤维细胞生长因子(fibroblast growth factor,FGF),可以由内皮细胞、平滑肌细胞、巨噬细胞分泌。它的作用是促进内皮细胞的游走和平滑肌细胞的增殖,不能使平滑肌细胞游走。能够促进新血管形成,修复损害的内皮细胞,促进成纤维细胞有丝分裂以及中胚层细胞的生长,在创伤愈合及肢体再生中发挥作用。FGF被认为是病灶形成促进因子,但从修复角度看它也有有利的一面,其功能强大,具有深层修复作用,在现代临床医学及外科手术和美容手术中发挥着不可估量的巨大作用。
表皮生长因子(EGF)是一种由53个氨基酸残基组成的耐热单链低分子多肽。EGF与靶细胞上的EGF受体特异性识别结合后,发生一系列生化反应,最终可促进靶细胞的DNA合成及有丝分裂。EGF无糖基部位,非常稳定,耐热耐酸,广泛存在于体液和多种腺体中。EGF作用广泛,对消化系统具有广泛的生物效应,可刺激靶细胞DNA合成,调节细胞防御及胃肠道分泌,可作用于壁细胞,抑制胃酸和胃蛋白酶分泌等。
磷酸腺苷是一种辅酶,有改善肌体代谢的作用,参与体内脂肪、蛋白质、糖、核酸及核苷酸的代谢,同时又是体内能量的主要来源。适用于细胞损伤后细胞酶减退引起的疾病。动物试验发现本品对心肌细胞的电生理有明显作用,可抑制慢反应细胞的钙离子内流,阻断和延长房室结折返环路的前向传导,大剂量尚可阻断房室旁路的折返性,具有增强迷走神经的作用,可用室上性心动过速。
胎盘组织液,即人胎盘组织液。活性成份为人胎盘组织经酸水解后的混合物,辅料为氯化钠。本品为淡黄色澄明液体。主要用于治疗妇科、皮肤科一些慢性炎症;手术后粘连、疤痕孪缩以及气管炎等慢性病。
优选地,该原料中包含大蜚蠊80~120份,黄芪25~35份,人参5~15份,没药1~5份,乳香1~5份,愈创木5~15份。
更优选地,该原料中包含大蜚蠊100g,黄芪30g,人参10g,没药3g,乳香3g,愈创木10g。
优选地,该原料中还包含成纤维细胞生长因子8~12份,表皮生长因子4~6份,磷酸腺苷1~3份,胎盘组织液1~3份。
更优选地,该原料中还包含成纤维细胞生长因子10g,表皮生长因子5g,磷酸腺苷2ml,胎盘组织液2ml。
步骤2中,将大蜚蠊用56°白酒浸泡五天,然后进行萃取,得到萃取液100ml。
步骤3中,将黄芪、人参、没药、乳香、愈创木,加水500ml煎煮,再加热浓缩为100ml,然后过滤,保留滤液。
步骤5中,将步骤2和步骤3所得的液体按体积比1:1混合,得到200ml混合液,再加入步骤4所得的混合物,混合均匀。
本发明还提供了该方法制备的用于皮肤损伤后预防萎缩性疤痕外用液。
该外用液在皮肤损伤清创缝合使伤口基本愈合后,从第8天开始涂抹,一天涂抹3回,每回在第一次涂抹药液吸收后,再连续重复涂抹2次。
下面结合实施例对本发明提供的用于皮肤损伤后预防萎缩性疤痕外用液及其制备方法做更进一步描述。
实施例1
一种用于皮肤损伤后预防萎缩性疤痕外用液的制备方法,其包含:
步骤1、按比例称取各原料。
该原料包含大蜚蠊、黄芪、人参、没药、乳香、愈创木、白酒、水,以及成纤维细胞生长因子、表皮生长因子、磷酸腺苷、胎盘组织液。
优选地,该原料中包含大蜚蠊100g,黄芪30g,人参10g,没药3g,乳香3g,愈创木10g。
该原料中还包含成纤维细胞生长因子10g,表皮生长因子5g,磷酸腺苷2ml,胎盘组织液2ml。
步骤2、将大蜚蠊用56°白酒浸泡五天,然后进行萃取,得到萃取液100ml。
步骤3、将黄芪、人参、没药、乳香、愈创木,加水500ml煎煮,再加热浓缩为100ml,然后过滤,保留滤液。
步骤4、将成纤维细胞生长因子、表皮生长因子、磷酸腺苷、胎盘组织液混合均匀。
步骤5、将步骤2和步骤3所得的液体按体积比1:1混合,得到200ml混合液,再加入步骤4所得的混合物,混合均匀后装瓶密封备用。
本实施例还提供了该方法制备的用于皮肤损伤后预防萎缩性疤痕外用液。
该外用液在皮肤损伤清创缝合使伤口基本愈合后,从第8天开始涂抹,一天涂抹3回,每回在第一次涂抹药液吸收后,再连续重复涂抹2次。
实施例2
一种用于皮肤损伤后预防萎缩性疤痕外用液的制备方法,其包含:
步骤1、按比例称取各原料。
该原料包含大蜚蠊、黄芪、人参、没药、乳香、愈创木、白酒、水,以及成纤维细胞生长因子、表皮生长因子、磷酸腺苷、胎盘组织液。
优选地,该原料中包含大蜚蠊80g,黄芪25g,人参5g,没药1g,乳香1g,愈创木5g。
该原料中还包含成纤维细胞生长因子8g,表皮生长因子4g,磷酸腺苷1ml,胎盘组织液1ml。
步骤2、将大蜚蠊用56°白酒浸泡五天,然后进行萃取,得到萃取液100ml。
步骤3、将黄芪、人参、没药、乳香、愈创木,加水500ml煎煮,再加热浓缩为100ml,然后过滤,保留滤液。
步骤4、将成纤维细胞生长因子、表皮生长因子、磷酸腺苷、胎盘组织液混合均匀。
步骤5、将步骤2和步骤3所得的液体按体积比1:1混合,得到200ml混合液,再加入步骤4所得的混合物,混合均匀后装瓶密封备用。
本实施例还提供了该方法制备的用于皮肤损伤后预防萎缩性疤痕外用液。
该外用液在皮肤损伤清创缝合使伤口基本愈合后,从第8天开始涂抹,一天涂抹3回,每回在第一次涂抹药液吸收后,再连续重复涂抹2次。
实施例3
一种用于皮肤损伤后预防萎缩性疤痕外用液的制备方法,其包含:
步骤1、按比例称取各原料。
该原料包含大蜚蠊、黄芪、人参、没药、乳香、愈创木、白酒、水,以及成纤维细胞生长因子、表皮生长因子、磷酸腺苷、胎盘组织液。
优选地,该原料中包含大蜚蠊120g,黄芪35g,人参15g,没药5g,乳香5g,愈创木15g。
该原料中还包含成纤维细胞生长因子12g,表皮生长因子6g,磷酸腺苷3ml,胎盘组织液3ml。
步骤2、将大蜚蠊用56°白酒浸泡五天,然后进行萃取,得到萃取液100ml。
步骤3、将黄芪、人参、没药、乳香、愈创木,加水500ml煎煮,再加热浓缩为100ml,然后过滤,保留滤液。
步骤4、将成纤维细胞生长因子、表皮生长因子、磷酸腺苷、胎盘组织液混合均匀。
步骤5、将步骤2和步骤3所得的液体按体积比1:1混合,得到200ml混合液,再加入步骤4所得的混合物,混合均匀后装瓶密封备用。
本实施例还提供了该方法制备的用于皮肤损伤后预防萎缩性疤痕外用液。
该外用液在皮肤损伤清创缝合使伤口基本愈合后,从第8天开始涂抹,一天涂抹3回,每回在第一次涂抹药液吸收后,再连续重复涂抹2次。
本发明各实施例提供的外用液及其制备方法,制备的成品药液主要是用于皮肤的物理性损伤在医疗处理后的疤痕预防。该配方通过在四川、河南二地,在美容店为顾客,以及在医院手术后免费为病人使用,普遍反映其效果较同类产品见效快,而且基本不留疤痕,特别是萎缩性疤痕。
本发明提供的用于皮肤损伤后预防萎缩性疤痕外用液及其制备方法,能够达到修复表皮组织、防腐生肌、愈后不留疤痕特别是萎缩性疤痕等效果,外用没有副作用,而且药物配方简单,使用方便,经济实惠。能够针对性解决具有发生萎缩的疤痕的皮肤再生修复能力弱的问题。
尽管本发明的内容已经通过上述优选实施例作了详细介绍,但应当认识到上述的描述不应被认为是对本发明的限制。在本领域技术人员阅读了上述内容后,对于本发明的多种修改和替代都将是显而易见的。因此,本发明的保护范围应由所附的权利要求来限定。
Claims (10)
1.一种用于皮肤损伤后预防萎缩性疤痕外用液的制备方法,其特征在于,所述的方法包含:
步骤1、按比例称取各原料;所述的原料包含大蜚蠊、黄芪、人参、没药、乳香、愈创木、白酒、水,以及成纤维细胞生长因子、表皮生长因子、磷酸腺苷、胎盘组织液;
步骤2、将大蜚蠊用白酒浸泡,然后进行萃取;
步骤3、将黄芪、人参、没药、乳香、愈创木,加水煎煮,再继续加热浓缩,然后过滤,保留滤液;
步骤4、将成纤维细胞生长因子、表皮生长因子、磷酸腺苷、胎盘组织液混合均匀;
步骤5、将步骤2和步骤3所得的液体混合,再加入步骤4所得的混合物,混合均匀后装瓶密封备用。
2.如权利要求1所述的用于皮肤损伤后预防萎缩性疤痕外用液的制备方法,其特征在于,所述的原料中包含大蜚蠊80~120份,黄芪25~35份,人参5~15份,没药1~5份,乳香1~5份,愈创木5~15份。
3.如权利要求2所述的用于皮肤损伤后预防萎缩性疤痕外用液的制备方法,其特征在于,所述的原料中包含大蜚蠊100g,黄芪30g,人参10g,没药3g,乳香3g,愈创木10g。
4.如权利要求1所述的用于皮肤损伤后预防萎缩性疤痕外用液的制备方法,其特征在于,所述的原料中还包含成纤维细胞生长因子8~12份,表皮生长因子4~6份,磷酸腺苷1~3份,胎盘组织液1~3份。
5.如权利要求4所述的用于皮肤损伤后预防萎缩性疤痕外用液的制备方法,其特征在于,所述的原料中还包含成纤维细胞生长因子10g,表皮生长因子5g,磷酸腺苷2ml,胎盘组织液2ml。
6.如权利要求1所述的用于皮肤损伤后预防萎缩性疤痕外用液的制备方法,其特征在于,所述的步骤2中,将大蜚蠊用56°白酒浸泡五天,然后进行萃取,得到萃取液100ml。
7.如权利要求1所述的用于皮肤损伤后预防萎缩性疤痕外用液的制备方法,其特征在于,所述的步骤3中,将黄芪、人参、没药、乳香、愈创木,加水500ml煎煮,再加热浓缩为100ml,然后过滤,保留滤液。
8.如权利要求1所述的用于皮肤损伤后预防萎缩性疤痕外用液的制备方法,其特征在于,所述的步骤5中,将步骤2和步骤3所得的液体按体积比1:1混合,得到200ml混合液,再加入步骤4所得的混合物,混合均匀。
9.一种如权利要求1~8中任意一项所述的方法制备的用于皮肤损伤后预防萎缩性疤痕外用液。
10.如权利要求9所述的用于皮肤损伤后预防萎缩性疤痕外用液,其特征在于,所述的外用液在皮肤损伤清创缝合使伤口基本愈合后,从第8天开始涂抹,一天涂抹3回,每回在第一次涂抹药液吸收后,再连续重复涂抹2次。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110689426.2A CN113198003A (zh) | 2021-06-22 | 2021-06-22 | 一种用于皮肤损伤后预防萎缩性疤痕外用液及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110689426.2A CN113198003A (zh) | 2021-06-22 | 2021-06-22 | 一种用于皮肤损伤后预防萎缩性疤痕外用液及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113198003A true CN113198003A (zh) | 2021-08-03 |
Family
ID=77022588
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110689426.2A Pending CN113198003A (zh) | 2021-06-22 | 2021-06-22 | 一种用于皮肤损伤后预防萎缩性疤痕外用液及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113198003A (zh) |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101204523A (zh) * | 2006-12-20 | 2008-06-25 | 刘云机 | 一种祛除疤痕、斑、皱纹的配方 |
CN101721458A (zh) * | 2009-10-30 | 2010-06-09 | 葛龙海 | 一种人胎盘组织液的制备方法 |
CN102895526A (zh) * | 2012-10-31 | 2013-01-30 | 唐和斌 | 一种治疗烧烫伤的外用生肤油及其制备方法和应用 |
CN103860449A (zh) * | 2014-03-18 | 2014-06-18 | 于法周 | 一种具有祛除妊娠纹功效的护肤制品及其制备方法 |
CN104958394A (zh) * | 2015-06-30 | 2015-10-07 | 桂林华诺威基因药业有限公司 | 一种治疗烫伤的外用生肤油及其制备方法 |
CN105363021A (zh) * | 2015-11-13 | 2016-03-02 | 邢月军 | 促进创面愈合的凝胶 |
CN105999154A (zh) * | 2016-06-07 | 2016-10-12 | 宋伟亮 | 祛疤液及其制备方法 |
CN106511251A (zh) * | 2016-12-27 | 2017-03-22 | 成都祥和康生物科技有限公司 | 一种人源干细胞生物美容原料及其制备方法 |
CN107072765A (zh) * | 2014-06-17 | 2017-08-18 | 科尼尔赛德生物医学公司 | 用于治疗后眼病症的方法和装置 |
CN107485675A (zh) * | 2017-08-28 | 2017-12-19 | 徐文明 | 一种创伤再生修复用化腐生肌粉及制备方法和使用方法 |
CN107837322A (zh) * | 2017-12-22 | 2018-03-27 | 长沙爱扬医药科技有限公司 | 一种促进创面愈合的外用中药组合物 |
CN108261361A (zh) * | 2018-02-09 | 2018-07-10 | 广东科玮生物技术股份有限公司 | 一种含有细胞生长因子的祛痘修复膏及其制备方法 |
CN108853481A (zh) * | 2018-07-31 | 2018-11-23 | 韩孝 | 用于细胞激活再生的组合物及其制备方法和应用 |
CN108852895A (zh) * | 2018-08-08 | 2018-11-23 | 宁波美奈生物科技有限公司 | 一种用于皮肤祛皱修复的化妆品组合物及其产品 |
-
2021
- 2021-06-22 CN CN202110689426.2A patent/CN113198003A/zh active Pending
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101204523A (zh) * | 2006-12-20 | 2008-06-25 | 刘云机 | 一种祛除疤痕、斑、皱纹的配方 |
CN101721458A (zh) * | 2009-10-30 | 2010-06-09 | 葛龙海 | 一种人胎盘组织液的制备方法 |
CN102895526A (zh) * | 2012-10-31 | 2013-01-30 | 唐和斌 | 一种治疗烧烫伤的外用生肤油及其制备方法和应用 |
CN103860449A (zh) * | 2014-03-18 | 2014-06-18 | 于法周 | 一种具有祛除妊娠纹功效的护肤制品及其制备方法 |
CN107072765A (zh) * | 2014-06-17 | 2017-08-18 | 科尼尔赛德生物医学公司 | 用于治疗后眼病症的方法和装置 |
CN104958394A (zh) * | 2015-06-30 | 2015-10-07 | 桂林华诺威基因药业有限公司 | 一种治疗烫伤的外用生肤油及其制备方法 |
CN105363021A (zh) * | 2015-11-13 | 2016-03-02 | 邢月军 | 促进创面愈合的凝胶 |
CN105999154A (zh) * | 2016-06-07 | 2016-10-12 | 宋伟亮 | 祛疤液及其制备方法 |
CN106511251A (zh) * | 2016-12-27 | 2017-03-22 | 成都祥和康生物科技有限公司 | 一种人源干细胞生物美容原料及其制备方法 |
CN107485675A (zh) * | 2017-08-28 | 2017-12-19 | 徐文明 | 一种创伤再生修复用化腐生肌粉及制备方法和使用方法 |
CN107837322A (zh) * | 2017-12-22 | 2018-03-27 | 长沙爱扬医药科技有限公司 | 一种促进创面愈合的外用中药组合物 |
CN108261361A (zh) * | 2018-02-09 | 2018-07-10 | 广东科玮生物技术股份有限公司 | 一种含有细胞生长因子的祛痘修复膏及其制备方法 |
CN108853481A (zh) * | 2018-07-31 | 2018-11-23 | 韩孝 | 用于细胞激活再生的组合物及其制备方法和应用 |
CN108852895A (zh) * | 2018-08-08 | 2018-11-23 | 宁波美奈生物科技有限公司 | 一种用于皮肤祛皱修复的化妆品组合物及其产品 |
Non-Patent Citations (7)
Title |
---|
周易等: "黄芪提取物联合表皮生长因子治疗大鼠皮肤烫伤的实验研究", 《中国临床药理学与治疗学》 * |
朱雪辉等: "康复新液治疗外伤创面愈合的疗效浅析", 《当代医学》 * |
杨胜群等: "美洲大蠊水提取物对小鼠烫伤模型的影响", 《中国实验方剂学杂志》 * |
杨邦英: "胎盘组织液治疗疤痕疙瘩及局限性硬皮病体会", 《安徽医学》 * |
王婕然等: "中药外用治疗皮肤创伤修复研究进展", 《动物医学进展》 * |
陈办成等: "碱性成纤维细胞生长因子对皮肤萎缩性瘢痕中成纤维细胞的作用", 《中国皮肤性病学杂志》 * |
魏操等: "美洲大蠊提取物对大鼠皮肤创伤修复机制探讨", 《安徽医科大学学报》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103768567B (zh) | 一种黑膏药及其制备方法 | |
KR102355277B1 (ko) | 골절 회복 및 뼈 재생 속도 향상용 산제, 환제 또는 액제 형태의 생약재 조성물 및 이를 이용한 산제 또는 환제 또는 액제 형태의 생약제제 | |
CN108186711A (zh) | 促进伤口愈合的药物组合物 | |
CN100434109C (zh) | 一种治疗烧烫伤的药膏及其制造方法 | |
CN101912518A (zh) | 补肾壮阳胶囊 | |
CN1048156C (zh) | 参芪生发精 | |
CN112516229A (zh) | 一种内病外治的中药组合物配方及制备工艺 | |
CN101332271A (zh) | 一种治疗烧烫伤的外用药物组合物 | |
CN102940817B (zh) | 一种用于治疗坐骨神经痛的丸剂 | |
CN113198003A (zh) | 一种用于皮肤损伤后预防萎缩性疤痕外用液及其制备方法 | |
CN104288055A (zh) | 一种含有水母雪莲花的中草药组合物及其制备方法和应用 | |
CN107412437A (zh) | 一种治疗风湿的药酒及其制备方法 | |
CN105816755A (zh) | 一种治疗腰椎、颈椎风湿骨病的乌龙通痹丸 | |
CN102755371B (zh) | 用于辅助治疗断肢、指再植的中药 | |
CN105168091A (zh) | 一种祛红血丝面膜粉及其制备方法 | |
CN111419925A (zh) | 一种快速提高性功能的中药外用制剂及其制备方法 | |
CN103285174A (zh) | 一种用于修复疤痕的护理药膏 | |
CN104623040A (zh) | 一种用于创口杀菌消炎的护理组合物及其制备方法 | |
CN109045204A (zh) | 一种治疗烧伤和烫伤的中药液及其制备方法 | |
CN109846861B (zh) | 一种蒙药外用贴膏及其制备方法 | |
CN102526382A (zh) | 一种消肿止痛的膏药 | |
CN106860767A (zh) | 一种用于促进疮伤愈合的中药制剂及其制备方法 | |
CN1078077C (zh) | 无疤痕中性烧伤膏及其制备方法 | |
CN101209338A (zh) | 一种治疗皮肤血管瘤的中药药物 | |
CN111905021A (zh) | 一种外伤专用膏药 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210803 |
|
RJ01 | Rejection of invention patent application after publication |